Literature DB >> 19661231

Role of periostin and interleukin-4 in recurrence of pterygia.

Chuan-Hui Kuo1, Dai Miyazaki, Keiko Yakura, Kaoru Araki-Sasaki, Yoshitsugu Inoue.   

Abstract

PURPOSE: To identify the candidate genes for pterygia recurrence from a pterygia transcriptome and to analyze their transcriptional regulation and functional relationships.
METHODS: Transcriptional networks for pterygia recurrence were constructed using network analysis that was applied to 184 genes that showed a significant twofold change in the whole genome. Of the identified recurrence-related candidate genes in the major networks, periostin and IL-4 were analyzed for transcriptional relationships using pterygia-derived fibroblasts. Immunohistochemical analysis was used to study pterygia tissue. Effector candidate molecule for recurrence periostin was analyzed for cell adhesive function.
RESULTS: The pterygia transcriptome was divided into four major biological networks with high significance scores (P < 10(-17)). The classifier with the highest accuracy using the support vector machine algorithm was periostin, which was successfully linked to the network of cell cycle, connective tissue development and function, and cell morphology. Analyses using pterygia-derived fibroblasts showed that periostin was required for cell adhesion that was mediated by a presumed pterygia-related extracellular matrix protein, fibronectin. Periostin was found to be transcriptionally induced by IL-4. The IL-4-stimulated periostin induction was suppressed by MAP kinase/ERK kinase 1 inhibitor, indicating an involvement of the MAP kinase pathway. Pathologically, IL-4 was transcriptionally elevated in recurrent pterygia tissue and was localized to perivascular tissues and endothelial cells in the stroma of the subconjunctiva of pterygia.
CONCLUSIONS: Periostin is induced by IL-4 and is involved in the fibronectin-mediated pterygia fibroblast adhesion. These findings indicate that periostin probably promotes the recurrence of pterygia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19661231     DOI: 10.1167/iovs.09-4022

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  6 in total

Review 1.  Aberrant expression of genes and proteins in pterygium and their implications in the pathogenesis.

Authors:  Qing-Yang Feng; Zi-Xuan Hu; Xi-Ling Song; Hong-Wei Pan
Journal:  Int J Ophthalmol       Date:  2017-06-18       Impact factor: 1.779

2.  Comparative evaluation of lymphatic vessels in primary versus recurrent pterygium.

Authors:  S Ling; Q Li; H Lin; W Li; T Wang; H Ye; J Yang; X Jia; Y Sun
Journal:  Eye (Lond)       Date:  2012-09-14       Impact factor: 3.775

3.  The efficacy of fascial granuloma excision with conjunctival autografting after pterygium surgery.

Authors:  Hui-Ya Fan; Zi-Lin Chen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-07-11       Impact factor: 3.117

4.  Proliferative Effects of Histamine on Primary Human Pterygium Fibroblasts.

Authors:  Zhenwei Qin; Qiuli Fu; Lifang Zhang; Houfa Yin; Xiuming Jin; Qiaomei Tang; Danni Lyu; Ke Yao
Journal:  Mediators Inflamm       Date:  2016-10-30       Impact factor: 4.711

5.  Expression profiling suggests the involvement of hormone-related, metabolic, and Wnt signaling pathways in pterygium progression.

Authors:  Jiarui Li; Tianchang Tao; Yingying Yu; Ningda Xu; Wei Du; Mingwei Zhao; Zhengxuan Jiang; Lvzhen Huang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-14       Impact factor: 6.055

6.  Proteomic analysis in pterygium; upregulated protein expression of ALDH3A1, PDIA3, and PRDX2.

Authors:  Sun Woong Kim; Jonghoon Lee; Boram Lee; Taiyoun Rhim
Journal:  Mol Vis       Date:  2014-08-27       Impact factor: 2.367

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.